Difference between revisions of "Eluvixtamab (AMG-330)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic") |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
| (13 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | Bispecific T-cell engager | + | Bispecific T-cell engager antibody that engages CD33 and CD3 |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMG-330 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
| − | |||
| − | [[Category: | + | [[Category:Intravenous medications]] |
| + | |||
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
| − | + | [[Category:Anti-CD33-CD3 bispecific antibodies]] | |
| − | [[Category:Anti-CD33 | ||
| − | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 00:14, 18 October 2023
Mechanism of action
Bispecific T-cell engager antibody that engages CD33 and CD3
Also known as
- Code name: AMG-330